The progress of psoriasis care in Italy is deeply shaped by variations in healthcare systems across regions, since the nation's decentralized National Health Service empowers local authorities to oversee healthcare funding, reimbursement methods, and treatment availability autonomously. In the past, managing psoriasis primarily depended on topical corticosteroids, phototherapy, and traditional systemic treatments like methotrexate and cyclosporine, especially in publicly funded hospitals focused on budget control. Nevertheless, in the last ten years, Italy has seen a surge in the use of biologic medications targeting inflammatory processes such as TNF-α, IL-17, and IL-23, which have shown notable improvements in skin health and long-term disease management. The access to biologics differs regionally, with northern regions like Lombardy and Emilia-Romagna usually leading in adoption rates due to better healthcare funding and a more developed dermatology system compared to southern areas. Financial constraints on regional health budgets have sped up the move toward biosimilars, which deliver similar therapeutic effectiveness to original biologics but at lower costs. Italian healthcare officials actively support biosimilar switching policies and cost-saving initiatives to enhance treatment accessibility while ensuring fiscal responsibility.

The arrival of biosimilars has broadened the eligibility criteria for treatments, allowing a greater number of patients with moderate-to-severe psoriasis to obtain advanced therapies via public health systems. Furthermore, national guidelines and real-world data gathered from dermatology databases assist doctors in refining treatment choices and tracking long-term safety effects. As Italy strives to balance clinical progress with cost-effectiveness, the landscape of psoriasis treatment showcases a gradual shift from conventional therapies to targeted biologics and biosimilars, backed by increasing medical expertise, regional policy adjustments, and a rising patient demand for effective long-term management solutions.According to the research report, " Italy Psoriasis Treatment Market Overview, 2031," published by Bonafide Research, the Italy Psoriasis Treatment market is expected to reach a market size of more than USD 1,52 Billion by 2031. The Italian market for psoriasis treatment is heavily influenced by local procurement policies and regional tender processes, which dictate how hospitals obtain high-expense biologic therapies and shape prescribing behaviors throughout public health facilities. Hospital tenders promote competitive pricing among drug manufacturers, encouraging the adoption of biosimilars and cost-effective treatments to manage healthcare costs while guaranteeing patient access to advanced therapies. Consequently, pharmaceutical companies are increasingly partnering with regional health agencies and hospital networks to obtain procurement agreements and strengthen market involvement. The growth of specialized dermatology centers across Italy has further enhanced treatment access, furnishing patients with expert care and facilitating the early start of advanced therapies for moderate-to-severe psoriasis.

These centers function as focal points for clinical studies, patient education, and interdisciplinary care that includes dermatologists, rheumatologists, and immunology experts. Collaborations between research organizations in Italy and international pharmaceutical firms have enhanced innovation by enabling clinical trials, studies based on real-world evidence, and the launch of new biologic therapies. Market potential is particularly strong in procurement channels within hospitals, where the competitive bidding processes favor producers that provide cost-effective but clinically sound treatments. Furthermore, the rising presence of biosimilars offers significant growth potential by increasing access to advanced therapies and lowering healthcare expenses for the public system. Digital health projects and teledermatology services are also becoming important tools for enhancing patient monitoring and encouraging treatment compliance in various regions. Italy psoriasis treatment market by type is divided into plaque psoriasis, psoriatic arthritis and others.

In Italy, plaque psoriasis is the most prevalent condition diagnosed, representing the largest share of dermatological visits and the need for biologic treatments. The nation's universal healthcare, alongside well-established dermatological infrastructures in regions like Lombardy, Lazio, and Emilia-Romagna, has enhanced the rates of early diagnosis and referrals. Clinicians in Italy are increasingly utilizing stratified treatment approaches, which means that patients with moderate-to-severe plaque psoriasis quickly progress to advanced systemic or biologic therapies if topical treatments do not work. Psoriatic arthritis PsA is also receiving more focus from healthcare professionals due to rising awareness among rheumatologists and the incorporation of interdisciplinary care teams. Improved screening initiatives and better cooperation between dermatology and rheumatology facilities have helped to decrease the rates of underdiagnosis, which previously hindered treatment accessibility. The management of PsA in Italy primarily depends on TNF inhibitors and emerging IL-17/IL-23 biologics, which benefit from national reimbursement policies.

The others category, encompassing guttate, inverse, pustular, and erythrodermic psoriasis, includes a smaller yet complex group that requires specialized treatment in higher-level medical facilities. These conditions often lead to hospitalization or necessitate expensive biologic medications due to the severity of the disease. Variations in regional healthcare affect access to treatments; northern areas typically see greater use of biologics compared to southern regions due to disparities in healthcare resources and funding. Patient support organizations and awareness initiatives have also played a role in increasing diagnosis rates, fueling market growth across all categories. As Italy moves towards personalized medicine, treatment strategies are becoming more focused on disease types, associated conditions, and patient feedback, which is shifting preferences toward targeted treatments for plaque psoriasis and PsA while still meeting the essential therapeutic needs for rarer psoriasis types.Italy psoriasis treatment market by treatment type is divided into biologics drugs, systemic drugs, topical drugs, phototherapy and others. The landscape of psoriasis treatments in Italy is changing quickly, with biologic medications becoming the leading area of growth due to their higher effectiveness and enhanced safety compared to older systemic options.

Access for patients has improved significantly, thanks to national insurance coverage from the Italian Medicines Agency AIFA and local formularies, particularly for those with moderate to severe conditions. Despite this, financial pressures on local healthcare funds have sped up the use of biosimilars, especially for TNF blockers, assisting hospitals in controlling costs while still achieving good clinical results. Systemic medications, such as methotrexate and cyclosporine, continue to be common first-line treatments before moving to biologics, especially in smaller facilities or areas with strict prescribing limits. Topical treatments still lead in managing mild psoriasis, backed by strong prescribing patterns from general practitioners and dermatologists, as they are budget-friendly and easily available at local pharmacies. At the same time, phototherapy remains consistently utilized in specialized dermatology practices, especially for individuals who opt for non-systemic methods or cannot use biologics. Progress in home-use phototherapy devices is slowly enhancing convenience, but take-up remains limited due to reimbursement issues.

The others treatment category, which includes new oral small-molecule therapies and combination treatments, is starting to gain momentum as doctors aim for individualized strategies for challenging or hard-to-treat cases. Italian guidelines promote a gradual approach to therapy, focusing on patient oversight and integrated care. Ongoing pharmaceutical advancements, along with increased clinical research in Italian universities, continue to roll out the next generation of biologics and targeted oral medications. The treatment landscape shows a well-rounded market where biologics encourage growth while systemic and topical options are essential parts of patient care plans.Italy psoriasis treatment market by distribution channel is divided into hospital pharmacies, retail pharmacies and e-commerce. In Italy, hospital pharmacies lead in the supply of advanced treatments for psoriasis, especially biologics and high-cost systemic therapies, owing to centralized purchasing and strict reimbursement regulations. Regional healthcare entities negotiate pricing contracts and tenders with drug manufacturers, ensuring expenses are controlled while also securing patient access to new treatments.

Several biologics are provided directly through hospital-based specialty pharmacies, allowing for close clinical supervision and adherence monitoring. Retail pharmacies are vital for offering topical therapies, supportive medications, and specific systemic drugs meant for mild to moderate psoriasis. The vast network of community pharmacies in Italy improves access, particularly in rural or less-served areas, enabling patients to easily follow long-term treatment plans. Pharmacists increasingly assist with patient education, adherence support, and referral to dermatologists when needed. At the same time, e-commerce channels are slowly growing, spurred by the adoption of digital health and regulatory changes that permit online pharmacy functions. While online distribution is still more restricted for prescription biologics because of strict regulations, it is gaining traction for over-the-counter products, skincare supplements, and prescription refills made easier through digital services.

Teledermatology and electronic prescriptions introduced during the COVID-19 pandemic have sped up this movement toward digital access. Italian consumers are becoming more accustomed to buying dermatology items online, especially in urban areas where digital use is higher. However, the hospital sector is projected to remain the key player for advanced therapies, while retail and e-commerce will continue to expand in supportive roles. Upcoming distribution patterns will likely focus on integrated digital platforms, home delivery of specialty medications, and better cooperation among hospitals, community pharmacies, and online vendors to enhance patient convenience and continuity of care. Considered in this report* Historic Year: 2020* Base year: 2025* Estimated year: 2026* Forecast year: 2031Aspects covered in this report* Psoriasis Treatment Market with its value and forecast along with its segments* Various drivers and challenges* On-going trends and developments* Top profiled companies* Strategic recommendationBy TypePlaque PsoriasisPsoriatic ArthritisOthersBy Treatment TypeBiologics DrugsSystemic DrugsTopical DrugsPhototherapyOthersBy Distribution ChannelHospital PharmaciesRetail Pharmaciese-Commerce.